Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 9/2019

01-09-2019 | Methotrexate | Review

Rheumatology practice in Japan: challenges and opportunities

Authors: Kenji Oku, Tatsuya Atsumi

Published in: Rheumatology International | Issue 9/2019

Login to get access

Abstract

This article aims to and describes the characteristics of rheumatology practice in Japan, focusing on the medical environment for the treatment of rheumatoid arthritis (RA). In Japan, the introduction of biological disease-modifying anti-rheumatic drugs (bDMARDs) has led to a significant paradigm shift in medical care; satisfactory safety outcomes have been demonstrated by periodic analysis, post-market surveillance and the development of guidelines via an industry–academia–government collaboration. Drug discontinuation is also considered an option, as well as medical economic analysis of any increase in the financial burden engendered by use of bDMARDs. Tocilizumab, a bDMARD established in Japan, was developed in an environment that facilitates translational research. The rheumatology community in Japan is expected to continue to develop novel therapies, while ensuring consistent quality of medical care despite limited healthcare resources.
Literature
1.
Kakinaka M, Kato RR (2013) Regulated medical fee schedule of the Japanese health care system. Int J Health Care Finance Econ 13(3–4):301–317CrossRefPubMed
2.
Ii M, Niu B (2018) Are Japanese people satisfied with their health care system and services? Empirical evidence from survey data. Health Policy 2018:28
3.
Sakai-Bizmark R, Goto R, Hiragi S, Tamura H (2018) Influence of Japan’s 2004 postgraduate training on ophthalmologist location choice, supply and distribution. BMC Med Educ 18(1):49CrossRefPubMedPubMedCentral
4.
Nomura K, Yano E, Aoki M, Kawaminami K, Endo H, Fukui T (2008) Improvement of residents’ clinical competency after the introduction of new postgraduate medical education program in Japan. Med Teach 30(6):e161–e169CrossRefPubMed
5.
Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S (2014) Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol 24(1):33–40CrossRefPubMed
6.
Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB (2017) Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int 37(9):1551–1557CrossRefPubMed
7.
Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M et al (2002) The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatol (Oxf) 41(7):793–800CrossRef
8.
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409–1417CrossRefPubMed
9.
Seto Y, Tanaka E, Inoue E, Nakajima A, Taniguchi A, Momohara S et al (2011) Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Mod Rheumatol 21(6):579–593CrossRefPubMedPubMedCentral
10.
Asai S, Nagai K, Takahashi N, Watanabe T, Matsumoto T, Asai N et al (2019) Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis. Int J Rheum Dis 22(2):207–213CrossRefPubMed
11.
Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y et al (2016) The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis 75(1):75–83CrossRefPubMed
12.
Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K et al (2017) Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open 3(1):e000363CrossRefPubMedPubMedCentral
13.
Tanaka Y, Atsumi T, Amano K, Harigai M, Ishii T, Kawaguchi O et al (2018) Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: subgroup analyses of four multinational phase 3 randomized trials. Mod Rheumatol 28(4):583–591CrossRefPubMed
14.
Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S (2015) Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 25(4):514–521CrossRefPubMedPubMedCentral
15.
Takeuchi T, Yamanaka H, Yamaoka K, Arai S, Toyoizumi S, DeMasi R et al (2019) Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: a post hoc analysis of clinical trial data. Mod Rheumatol 11:1–11
16.
Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S et al (2016) Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther 18:34CrossRefPubMedPubMedCentral
17.
Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H et al (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67(2):189–194CrossRefPubMed
18.
Koike R, Takeuchi T, Eguchi K, Miyasaka N (2007) Japan College of R. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17(6):451–458CrossRefPubMed
19.
Kato E, Sawada T, Tahara K, Hayashi H, Tago M, Mori H et al (2017) The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis 20(7):839–845CrossRefPubMed
20.
Sugimoto N, Nakajima A, Inoue E, Shidara K, Yamashita H, Mimori A et al (2017) Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis. Rheumatol Int 37(11):1871–1878CrossRefPubMed
21.
Muraguchi A, Nishimoto H, Kawamura N, Hori A, Kishimoto T (1986) B cell-derived BCGF functions as autocrine growth factor(s) in normal and transformed B lymphocytes. J Immunol 137(1):179–186PubMed
22.
Giordano V, De Falco G, Chiari R, Quinto I, Pelicci PG, Bartholomew L et al (1997) Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase. J Immunol 158(9):4097–4103
23.
Bellido T, Borba VZ, Roberson P, Manolagas SC (1997) Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 138(9):3666–3676CrossRefPubMed
24.
Kim H, Baumann H (1999) Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol 19(8):5326–5338CrossRefPubMedPubMedCentral
25.
Thiel S, Sommer U, Kortylewski M, Haan C, Behrmann I, Heinrich PC et al (2000) Termination of IL-6-induced STAT activation is independent of receptor internalization but requires de novo protein synthesis. FEBS Lett 470(1):15–19CrossRefPubMed
26.
Rana AK, Li Y, Dang Q, Yang F (2018) Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis. Int Immunopharmacol 65:348–359CrossRefPubMed
27.
28.
Wu Y, Liu J, Feng X, Yang P, Xu X, Hsu HC et al (2005) Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis. Arthritis Rheum 52(10):3257–3268CrossRefPubMed
29.
30.
Tanaka T, Ogata A, Narazaki M (2010) Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 6(6):843–854CrossRefPubMed
31.
Mima T, Nishimoto N (2008) Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 4(2):165–172CrossRefPubMed
32.
Kiely PD (2016) Biologic efficacy optimization—a step towards personalized medicine. Rheumatology 55(5):780–788CrossRefPubMed
33.
Ogata A, Kato Y, Higa S, Yoshizaki K (2018) IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol 14:1–29CrossRef
34.
35.
Kojima M, Nakayama T, Kawahito Y, Kaneko Y, Kishimoto M, Hirata S et al (2016) The process of collecting and evaluating evidences for the development of Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology 2014: utilization of GRADE approach. Mod Rheumatol 26(2):175–179CrossRefPubMed
36.
Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K et al (2018) Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol 24:1–10
37.
Kawahito Y (2016) Guidelines for the management of rheumatoid arthritis. Nihon Rinsho 74(6):939–943PubMed
38.
Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977CrossRef
39.
Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1–26CrossRefPubMed
40.
Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69(7):1286–1291CrossRefPubMedPubMedCentral
41.
Tanaka Y (2013) Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis 72(Suppl 2):ii124–i127CrossRefPubMed
42.
Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T et al (2014) Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis 73(3):536–543CrossRefPubMed
43.
Hirata A, Suenaga Y, Miyamura T, Matsui T, Tohma S, Suematsu E et al (2018) Effect of early treatment on physical function in daily management of rheumatoid arthritis: a 5-year longitudinal study of rheumatoid arthritis patients in the National Database of Rheumatic Diseases in Japan. Int J Rheum Dis 21(4):828–835CrossRefPubMed
44.
Shiroiwa T, Fukuda T, Ikeda S, Takura T (2017) New decision-making processes for the pricing of health technologies in Japan: the FY 2016/2017 pilot phase for the introduction of economic evaluations. Health Policy 121(8):836–841CrossRefPubMed
Metadata
Title
Rheumatology practice in Japan: challenges and opportunities
Authors
Kenji Oku
Tatsuya Atsumi
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 9/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04281-0

Other articles of this Issue 9/2019

Rheumatology International 9/2019 Go to the issue

Observational Research

Anterior uveitis in patients with spondyloarthropathies in a single US academic center: a retrospective study

Cases with a Message

Klippel–Feil syndrome misdiagnosed as spondyloarthropathy: case-based review

Observational Research

Leflunomide treatment in juvenile idiopathic arthritis

Cases with a Message

HLA-B27 spondyloarthritis and spotted fever rickettsiosis: case-based review

Systematic Review

Gout is associated with elevated risk of erectile dysfunction: a systematic review and meta-analysis

Review

Comorbidity burden in systemic sclerosis: beyond disease-specific complications
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits